Table 4 reports the most relevant clinical (i.e., Geriatric Depression Scale, GDS, Clinical Dementia Rating, CDR, and Hachinski Ischemic Score, HIS), genetic (i.e., APOE genotyping), and cerebrospinal fluid (i.e., Aβ42, t-tau, p-tau, Aβ42/p-tau) features of the noADMCI-noEEA and noADMCI-EEA groups. Here, MAPT is linked to depressive symptom measurement.